vs

Side-by-side financial comparison of AGENUS INC (AGEN) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

AGENUS INC is the larger business by last-quarter revenue ($34.2M vs $23.1M, roughly 1.5× PEDEVCO CORP). AGENUS INC runs the higher net margin — -31.0% vs -36.8%, a 5.8% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs 27.5%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 10.5%).

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

AGEN vs PED — Head-to-Head

Bigger by revenue
AGEN
AGEN
1.5× larger
AGEN
$34.2M
$23.1M
PED
Growing faster (revenue YoY)
PED
PED
+90.8% gap
PED
118.2%
27.5%
AGEN
Higher net margin
AGEN
AGEN
5.8% more per $
AGEN
-31.0%
-36.8%
PED
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
10.5%
AGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGEN
AGEN
PED
PED
Revenue
$34.2M
$23.1M
Net Profit
$-10.6M
$-8.5M
Gross Margin
Operating Margin
42.1%
-21.3%
Net Margin
-31.0%
-36.8%
Revenue YoY
27.5%
118.2%
Net Profit YoY
77.3%
-243.5%
EPS (diluted)
$0.09
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGEN
AGEN
PED
PED
Q4 25
$34.2M
$23.1M
Q3 25
$30.2M
$7.0M
Q2 25
$25.7M
$7.0M
Q1 25
$24.1M
$8.7M
Q4 24
$26.8M
$10.6M
Q3 24
$25.1M
$9.1M
Q2 24
$23.5M
$11.8M
Q1 24
$28.0M
$8.1M
Net Profit
AGEN
AGEN
PED
PED
Q4 25
$-10.6M
$-8.5M
Q3 25
$63.9M
$-325.0K
Q2 25
$-30.0M
$-1.7M
Q1 25
$-26.4M
$140.0K
Q4 24
$-46.8M
$5.9M
Q3 24
$-67.2M
$2.9M
Q2 24
$-54.8M
$2.7M
Q1 24
$-63.5M
$773.0K
Gross Margin
AGEN
AGEN
PED
PED
Q4 25
Q3 25
97.9%
Q2 25
99.1%
Q1 25
99.4%
Q4 24
99.6%
Q3 24
99.4%
Q2 24
99.5%
Q1 24
99.6%
Operating Margin
AGEN
AGEN
PED
PED
Q4 25
42.1%
-21.3%
Q3 25
-15.0%
-12.0%
Q2 25
-65.0%
-32.2%
Q1 25
-55.3%
1.7%
Q4 24
-96.5%
-12.9%
Q3 24
-125.5%
31.3%
Q2 24
-128.4%
22.3%
Q1 24
-117.4%
7.6%
Net Margin
AGEN
AGEN
PED
PED
Q4 25
-31.0%
-36.8%
Q3 25
211.4%
-4.7%
Q2 25
-116.8%
-24.0%
Q1 25
-109.6%
1.6%
Q4 24
-174.4%
56.0%
Q3 24
-267.7%
32.2%
Q2 24
-233.1%
22.7%
Q1 24
-226.6%
9.5%
EPS (diluted)
AGEN
AGEN
PED
PED
Q4 25
$0.09
$-2.23
Q3 25
$1.94
$0.00
Q2 25
$-1.00
$-0.02
Q1 25
$-1.03
$0.00
Q4 24
$-1.95
$2.69
Q3 24
$-3.08
$0.03
Q2 24
$-2.52
$0.03
Q1 24
$-3.04
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGEN
AGEN
PED
PED
Cash + ST InvestmentsLiquidity on hand
$3.0M
$3.2M
Total DebtLower is stronger
$44.7M
Stockholders' EquityBook value
$-271.1M
$207.4M
Total Assets
$226.8M
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGEN
AGEN
PED
PED
Q4 25
$3.0M
$3.2M
Q3 25
$3.5M
$10.9M
Q2 25
$9.5M
$8.5M
Q1 25
$18.5M
$10.4M
Q4 24
$40.4M
$4.0M
Q3 24
$44.8M
$4.6M
Q2 24
$93.7M
$6.1M
Q1 24
$52.9M
$13.3M
Total Debt
AGEN
AGEN
PED
PED
Q4 25
$44.7M
Q3 25
$34.2M
Q2 25
$33.9M
Q1 25
$33.6M
Q4 24
$33.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AGEN
AGEN
PED
PED
Q4 25
$-271.1M
$207.4M
Q3 25
$-274.1M
$115.4M
Q2 25
$-354.6M
$115.2M
Q1 25
$-341.8M
$116.2M
Q4 24
$-326.4M
$115.6M
Q3 24
$-292.3M
$106.5M
Q2 24
$-241.3M
$103.2M
Q1 24
$-201.4M
$100.0M
Total Assets
AGEN
AGEN
PED
PED
Q4 25
$226.8M
$375.9M
Q3 25
$233.9M
$135.9M
Q2 25
$185.2M
$136.8M
Q1 25
$200.2M
$145.6M
Q4 24
$226.3M
$128.3M
Q3 24
$238.5M
$114.3M
Q2 24
$292.4M
$111.0M
Q1 24
$256.6M
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGEN
AGEN
PED
PED
Operating Cash FlowLast quarter
$-16.6M
$-2.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGEN
AGEN
PED
PED
Q4 25
$-16.6M
$-2.1M
Q3 25
$-14.7M
$7.4M
Q2 25
$-20.2M
$-420.0K
Q1 25
$-25.6M
$5.9M
Q4 24
$-28.7M
$4.2M
Q3 24
$-53.3M
$8.3M
Q2 24
$-38.2M
$4.6M
Q1 24
$-38.2M
$-4.3M
Free Cash Flow
AGEN
AGEN
PED
PED
Q4 25
Q3 25
Q2 25
$-20.2M
Q1 25
$-25.6M
Q4 24
$-28.7M
Q3 24
$-53.3M
Q2 24
$-38.6M
Q1 24
$-38.2M
FCF Margin
AGEN
AGEN
PED
PED
Q4 25
Q3 25
Q2 25
-78.7%
Q1 25
-106.5%
Q4 24
-107.0%
Q3 24
-212.2%
Q2 24
-164.4%
Q1 24
-136.5%
Capex Intensity
AGEN
AGEN
PED
PED
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.3%
Q3 24
0.0%
Q2 24
2.0%
Q1 24
0.1%
Cash Conversion
AGEN
AGEN
PED
PED
Q4 25
Q3 25
-0.23×
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGEN
AGEN

Non Cash Royalty Revenue$31.1M91%
Other$3.2M9%

PED
PED

Segment breakdown not available.

Related Comparisons